RNA-Guided DNA Integration Using Tn7-Like Transposons
Summary
The USPTO published patent application US20260109980A1 filed by Samuel Henry Sternberg and Sanne Eveline Klompe on May 8, 2025, covering systems and methods that use Tn7-like transposons encoding CRISPR-Cas systems for programmable, RNA-guided DNA integration downstream of a genomic target site. The application claims priority to CPC classifications including C12N 15/113, C12N 9/22, and C12N 15/902. Parties researching gene-editing technologies involving transposon-based integration should monitor this application for competitive landscape implications.
“In certain embodiments, the present systems and methods use Tn7-like transposons that encode CRISPR-Cas systems for programmable, RNA-guided DNA integration.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.
What changed
The USPTO published a patent application (US20260109980A1) disclosing systems and methods for using Tn7-like transposons that encode CRISPR-Cas systems, enabling programmable, RNA-guided DNA integration downstream of a guide-RNA-recognized genomic target site.
Biotechnology and pharmaceutical companies active in gene-editing research should monitor this application's claims, as it may present freedom-to-operate considerations for parties developing transposon-based or CRISPR-directed DNA integration platforms.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS
Application US20260109980A1 Kind: A1 Apr 23, 2026
Inventors
Samuel Henry Sternberg, Sanne Eveline Klompe
Abstract
In certain embodiments, the present systems and methods use Tn7-like transposons that encode CRISPR-Cas systems for programmable, RNA-guided DNA integration. For example, the CRISPR-Cas machinery directs the Tn7 transposon-associated proteins to integrate DNA downstream of a target site (e.g., a genomic target site) recognized by a guide RNA (gRNA).
CPC Classifications
C12N 15/113 C12N 9/22 C12N 15/102 C12N 15/63 C12N 15/902 C12N 2310/20
Filing Date
2025-05-08
Application No.
19202829
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.